Vitex Pharmaceuticals

vitexpharma.com

Vitex Pharmaceuticals is a global leader in the contract manufacture of complementary medicine. From our state-of-the-art 26,000sqm best-in-class facility in Sydney, Australia, we are fully equipped to formulate, manufacture and package a wide variety of vitamins, minerals, herbal and nutritional supplements including tablets, softgel capsules, two-piece hardgel capsules and powders.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ANTI-PARASITIC DRUG HALTS CORONAVIRUS REPLICATION IN LAB-GROWN CELLS WITHIN 48 HOURS

GEN | April 06, 2020

news image

An anti-parasitic drug that is available around the world stops SARS-CoV-2 coronavirus from replicating in cells within a couple of days, according to findings from in vitro studies by Monash University’s Biomedicine Discovery Institute (BDI), working with the Peter Doherty Institute of Infection and Immunity. BDI research lead Kylie Wagstaff, PhD, said the studies showed that the drug, ivermectin, started to become effective against SARS-CoV-2 in lab-grown cells within just a day. “...

Read More

COVID-19 AND SARS-COV-2 NEW RESEARCH, VACCINE AND DRUG DEVELOPMENT NEWS

BioTechniques | April 15, 2020

news image

News covering COVID-19 is still to slow down, with this week’s big hitter being the announcement that US President Donald Trump has put funding for the WHO on hold pending a review. Accusing the WHO of “severely mismanaging and covering up” the threat, critics have been quick to respond, with the UN Secretary General António Guterres declaring now is “not the time to reduce the resources for the operations of the WHO…”. With the US contributing over $4...

Read More

ALLIED EXPANDS PHARMACEUTICAL PIPELINE BY FILING US PROVISIONAL PATENT FOR PSILOCYBIN BASED THERAPEUTICS

Allied Corp | October 21, 2020

news image

Allied Corp, an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues is pleased to announce the filing of a new United States provisional patent application entitled “PSILOCYBIN COMPOSITIONS AND FORMULATIONS AND THEIR USE IN TREATING MENTAL HEALTH DISORDERS AND IMPROVING MENTAL HEALTH”. The provisional patent application covers a novel combination of psilocybin and proprietary mushroom f...

Read More

PRACTICE MANAGEMENT

ASCENTAGE PHARMA PRESENTS UPDATES ON ITS GLOBAL CLINICAL DEVELOPMENT AT THE J.P. MORGAN 39TH ANNUAL HEALTHCARE CONFERENCE

Ascentage Pharma | January 14, 2021

news image

Ascentage Pharma, an around the world engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignant growths, persistent hepatitis B (CHB), and age-related illnesses, introduced at the J.P. Morgan 39th Annual Healthcare Conference (a virtual occasion) at night of January 13, Beijing Time. During the introduction, Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, furnished business refreshes with an attention on the organization's worldwide R&...

Read More
news image

ANTI-PARASITIC DRUG HALTS CORONAVIRUS REPLICATION IN LAB-GROWN CELLS WITHIN 48 HOURS

GEN | April 06, 2020

An anti-parasitic drug that is available around the world stops SARS-CoV-2 coronavirus from replicating in cells within a couple of days, according to findings from in vitro studies by Monash University’s Biomedicine Discovery Institute (BDI), working with the Peter Doherty Institute of Infection and Immunity. BDI research lead Kylie Wagstaff, PhD, said the studies showed that the drug, ivermectin, started to become effective against SARS-CoV-2 in lab-grown cells within just a day. “...

Read More
news image

COVID-19 AND SARS-COV-2 NEW RESEARCH, VACCINE AND DRUG DEVELOPMENT NEWS

BioTechniques | April 15, 2020

News covering COVID-19 is still to slow down, with this week’s big hitter being the announcement that US President Donald Trump has put funding for the WHO on hold pending a review. Accusing the WHO of “severely mismanaging and covering up” the threat, critics have been quick to respond, with the UN Secretary General António Guterres declaring now is “not the time to reduce the resources for the operations of the WHO…”. With the US contributing over $4...

Read More
news image

ALLIED EXPANDS PHARMACEUTICAL PIPELINE BY FILING US PROVISIONAL PATENT FOR PSILOCYBIN BASED THERAPEUTICS

Allied Corp | October 21, 2020

Allied Corp, an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues is pleased to announce the filing of a new United States provisional patent application entitled “PSILOCYBIN COMPOSITIONS AND FORMULATIONS AND THEIR USE IN TREATING MENTAL HEALTH DISORDERS AND IMPROVING MENTAL HEALTH”. The provisional patent application covers a novel combination of psilocybin and proprietary mushroom f...

Read More
news image

PRACTICE MANAGEMENT

ASCENTAGE PHARMA PRESENTS UPDATES ON ITS GLOBAL CLINICAL DEVELOPMENT AT THE J.P. MORGAN 39TH ANNUAL HEALTHCARE CONFERENCE

Ascentage Pharma | January 14, 2021

Ascentage Pharma, an around the world engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignant growths, persistent hepatitis B (CHB), and age-related illnesses, introduced at the J.P. Morgan 39th Annual Healthcare Conference (a virtual occasion) at night of January 13, Beijing Time. During the introduction, Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, furnished business refreshes with an attention on the organization's worldwide R&...

Read More